Lv1
92 积分 2023-03-14 加入
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
9天前
已完结
Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline
16天前
已完结
Is There Still Room for Monotherapy in EGFR -Mutated Non–Small Cell Lung Cancer?
1个月前
已完结
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors
4个月前
已完结
Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]
4个月前
已关闭
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
4个月前
已完结
Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes
4个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
4个月前
已完结
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
4个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
